The document concludes that specialized hair transplant techniques can be effective, with varying success rates depending on the donor area and patient factors.
A 31-year-old user experienced hair regrowth and no side effects after switching from finasteride to dutasteride and using minoxidil foam daily. They reported improved hair retention and shared their treatment routine, including a prescription for dutasteride and the use of minoxidil, while humorously discussing side effects and personal experiences.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
The conversation is about using finasteride and testosterone replacement therapy (TRT) for hair loss and their role in gender-affirming care. It debates whether these treatments are considered hormone replacement therapy (HRT) and their implications for both cisgender and transgender individuals.
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
Microneedling should target depths of 0.5mm to 1.5mm for hair loss, with weekly sessions at 1mm recommended. Combining microneedling with Minoxidil is common for improved results.